Narrative Evidence-synthesis Overall, the cost-effectiveness analyses reveal a clear trend. 30 of 39 ICERs (76.9%) demonstrate cost-effectiveness, with 21 ICERs positioned in the northeastern quadrant, indicating weak dominance below the EUR 25,000/QALY threshold.
← all excerpts
Breaking the habit: a systematic review of the cost-effectiveness of non-pharmacological and combined interventions for smoking cessation in Europe.
1
—
—